Airway-on-a-chip technology enables COVID-19 drug repurposing
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
List view / Grid view
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
A combination of computer simulations and fragment screening have uncovered 27 molecular binding sites on tubulin, a protein of the cell cytoskeleton.
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
After screening 4,500 compounds using induced pluripotent stem cells, researchers have identified one lead that could treat pulmonary arterial hypertension.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
Researchers have developed a platform named FAST to produce antibiotics that specifically target just the bacteria of interest.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
Researchers have developed their previously created brain organoid to test for potential drugs against Creutzfeldt-Jakob disease (CJD).
Scientists have created an assay to detect the protein cathepsin B in blood, a biomarker for a range of diseases.
Researchers have used fragment screening alongside computational docking to reveal 20 hit antiviral compounds against SARS-CoV-2.
Scientists have shown that culturing cells with a modified serum could allow drugs to be screened for toxicity earlier during research.
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.